Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Why the Current Interest in Ventyx Biosciences

March 7, 2023 0

The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus We like the fact that Ventyx …

Intellia Therapeutics Announces FDA Clearance of IND Application for NTLA-2002 Therapy for the Treatment of Hereditary Angioedema

March 2, 2023 0

Intellia Therapeutics Intellia Therapeutics (NTLA) announced that the U.S. FDA has cleared the company’s Investigational New …

Apellis Pharmaceuticals: A Biopharmaceutical Firm That We Like

February 23, 2023 0

Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) is a biopharma firm developing novel products for debilitating and …

Why Travere Therapeutics’ Stocks Did Not Fall During This Tuesday’s Bad Market

February 22, 2023 0

The Bear Market The volatility in the Bear stock market continues to plunge the values of …

Evaluating Regenxbio Clinical Performance of RGX-314 Using the Navxpress™ Manufacturing Platform Process

February 13, 2023 0

Prohost's Beliefs About the Status of the Market That the market is still volatile and Bear. …

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

February 8, 2023 0

Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' …

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

February 7, 2023 0

Xenon Pharmaceuticals Xenon Pharmaceuticals (XENE) - a clinical stage biopharmaceutical company developing novel treatments aimed at improving …

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

February 3, 2023 0

Merck KEYTRUDA Announcement Merck (MRK) announced today that Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination …

CytomX: Why Does Good News from This Firm Cause Its Stock to Move South Instead of North?

February 2, 2023 0

CytomX Therapeutics We posted several articles that brought good news from CytomX Therapeutics (CTMX), yet the …

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

February 2, 2023 0

It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. …

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001 Novel Gene Therapy for Refractory Angina

January 27, 2023 0

XyloCor Therapeutics Announced Positive Results for XC001 XyloCor Therapeutics announced the completion of the Phase 2 portion …

TG Therapeutics Launched FDA Approved Product BRIUMVI™ for Patients with Relapsing Forms of MS

January 27, 2023 0

TG Therapeutics TG Therapeutics (TGTX) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for …

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

January 20, 2023 0

Jazz Pharmaceuticals and Zymeworks Inc Announce Results of Zanidatamab Jazz Pharmaceuticals (JAZZ) and Zymeworks Inc. (ZYME)

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

January 19, 2023 0

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. (EDIT), announced that it has …

Ionis and Royalty Pharma Enter into a Royalty Agreement for Up to $1.1B

January 13, 2023 0

Ionis Pharmaceuticals and Royalty Pharma Ionis Pharmaceuticals (IONS) and Royalty Pharma plc (RPRX) announced that Royalty Pharma has …

Why Investors Have Enthusiasm for CureVac N.V.

January 10, 2023 0

CureVac N.V. in the News CureVac N.V. (CVAC) announced that after more than 10 years as …

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 5, 2023 1

CytomX and Moderna in the NEWS On January 05, 2023, CytomX Therapeutics (CTMX) and Moderna Inc (MRNA) announced a collaboration …

Stocks Outperforming Today

January 5, 2023 0

January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata …

Promising Stocks in the First Two Trading Days of 2023

January 4, 2023 0

The Stock Market in the New Year It is still too early to tell how the …

Gilead Sciences – Still Way Undervalued

December 29, 2022 0

Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Why the Current Interest in Ventyx Biosciences

Intellia Therapeutics Announces FDA Clearance of IND Application for NTLA-2002 Therapy for the Treatment of Hereditary Angioedema

Apellis Pharmaceuticals: A Biopharmaceutical Firm That We Like

Why Travere Therapeutics’ Stocks Did Not Fall During This Tuesday’s Bad Market

Evaluating Regenxbio Clinical Performance of RGX-314 Using the Navxpress™ Manufacturing Platform Process

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

CytomX: Why Does Good News from This Firm Cause Its Stock to Move South Instead of North?

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001 Novel Gene Therapy for Refractory Angina

TG Therapeutics Launched FDA Approved Product BRIUMVI™ for Patients with Relapsing Forms of MS

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

Ionis and Royalty Pharma Enter into a Royalty Agreement for Up to $1.1B

Why Investors Have Enthusiasm for CureVac N.V.

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Stocks Outperforming Today

Promising Stocks in the First Two Trading Days of 2023

Gilead Sciences – Still Way Undervalued